MXPA04008100A - Formulaciones de liberacion modificada de al menos una forma de tramadol. - Google Patents
Formulaciones de liberacion modificada de al menos una forma de tramadol.Info
- Publication number
- MXPA04008100A MXPA04008100A MXPA04008100A MXPA04008100A MXPA04008100A MX PA04008100 A MXPA04008100 A MX PA04008100A MX PA04008100 A MXPA04008100 A MX PA04008100A MX PA04008100 A MXPA04008100 A MX PA04008100A MX PA04008100 A MXPA04008100 A MX PA04008100A
- Authority
- MX
- Mexico
- Prior art keywords
- tramadol
- pharmaceutical composition
- release pharmaceutical
- modified release
- hours
- Prior art date
Links
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 title claims abstract description 449
- 229960004380 tramadol Drugs 0.000 title claims abstract description 447
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 title claims abstract description 416
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 238000009472 formulation Methods 0.000 title description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 78
- 238000000034 method Methods 0.000 claims abstract description 36
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000004090 dissolution Methods 0.000 claims abstract description 30
- 238000000338 in vitro Methods 0.000 claims abstract description 23
- 238000000576 coating method Methods 0.000 claims description 68
- 239000011248 coating agent Substances 0.000 claims description 66
- 239000003814 drug Substances 0.000 claims description 39
- 229940079593 drug Drugs 0.000 claims description 36
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 25
- 229920003176 water-insoluble polymer Polymers 0.000 claims description 24
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 claims description 23
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 23
- 229960003107 tramadol hydrochloride Drugs 0.000 claims description 23
- 229920003169 water-soluble polymer Polymers 0.000 claims description 23
- 239000004014 plasticizer Substances 0.000 claims description 22
- 229920001249 ethyl cellulose Polymers 0.000 claims description 20
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 20
- 239000000314 lubricant Substances 0.000 claims description 20
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 20
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 20
- 239000001856 Ethyl cellulose Substances 0.000 claims description 19
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 18
- 239000011230 binding agent Substances 0.000 claims description 18
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical group CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 16
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 16
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 16
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical group CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 11
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 11
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 9
- 230000036470 plasma concentration Effects 0.000 claims description 9
- 239000002547 new drug Substances 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 description 171
- 208000002193 Pain Diseases 0.000 description 59
- 230000036407 pain Effects 0.000 description 55
- TVYLLZQTGLZFBW-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol Chemical compound COC1=CC=CC(C2(O)C(CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-UHFFFAOYSA-N 0.000 description 54
- 229940054370 ultram Drugs 0.000 description 54
- 238000011282 treatment Methods 0.000 description 46
- 239000000902 placebo Substances 0.000 description 40
- 229940068196 placebo Drugs 0.000 description 40
- 238000013265 extended release Methods 0.000 description 24
- 230000008859 change Effects 0.000 description 22
- 201000008482 osteoarthritis Diseases 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 239000002207 metabolite Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 230000004044 response Effects 0.000 description 13
- 206010003246 arthritis Diseases 0.000 description 11
- 238000013461 design Methods 0.000 description 11
- 239000000945 filler Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 230000000202 analgesic effect Effects 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 230000002411 adverse Effects 0.000 description 8
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 8
- UWJUQVWARXYRCG-UHFFFAOYSA-N o-desmethyltramadol Chemical compound CN(C)CC1CCCCC1(O)C1=CC=CC(O)=C1 UWJUQVWARXYRCG-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229960000590 celecoxib Drugs 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 230000002028 premature Effects 0.000 description 7
- 238000013268 sustained release Methods 0.000 description 7
- 239000000730 antalgic agent Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000008199 coating composition Substances 0.000 description 5
- 235000020937 fasting conditions Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 208000000094 Chronic Pain Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000009597 pregnancy test Methods 0.000 description 4
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 229960001866 silicon dioxide Drugs 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 3
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000008930 Low Back Pain Diseases 0.000 description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000011978 dissolution method Methods 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960000371 rofecoxib Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 2
- 229920003082 Povidone K 90 Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- -1 citrate ester Chemical class 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940049654 glyceryl behenate Drugs 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 229940121367 non-opioid analgesics Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000000014 opioid analgesic Substances 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229940071138 stearyl fumarate Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940033134 talc Drugs 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical class C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- UWJUQVWARXYRCG-HIFRSBDPSA-N O-Desmethyltramadol Chemical compound CN(C)C[C@H]1CCCC[C@]1(O)C1=CC=CC(O)=C1 UWJUQVWARXYRCG-HIFRSBDPSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 201000000751 autosomal recessive congenital ichthyosis Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 239000011928 denatured alcohol Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000021153 full breakfast Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000000406 opioidergic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940087462 relafen Drugs 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 229940087652 vioxx Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Paints Or Removers (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35785102P | 2002-02-21 | 2002-02-21 | |
| PCT/US2003/004866 WO2003072025A2 (en) | 2002-02-21 | 2003-02-21 | Modified release formulations of at least one form of tramadol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04008100A true MXPA04008100A (es) | 2005-06-17 |
Family
ID=27765948
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04008100A MXPA04008100A (es) | 2002-02-21 | 2003-02-21 | Formulaciones de liberacion modificada de al menos una forma de tramadol. |
| MXPA04008164A MXPA04008164A (es) | 2002-02-21 | 2003-02-21 | Formas de dosificacion de liberacion controlada. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04008164A MXPA04008164A (es) | 2002-02-21 | 2003-02-21 | Formas de dosificacion de liberacion controlada. |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7780987B2 (enExample) |
| EP (2) | EP1476139B1 (enExample) |
| JP (3) | JP5069395B2 (enExample) |
| AT (1) | ATE536173T1 (enExample) |
| AU (2) | AU2003211146B2 (enExample) |
| CA (2) | CA2476496C (enExample) |
| CY (1) | CY1112517T1 (enExample) |
| DK (1) | DK1476138T3 (enExample) |
| ES (2) | ES2377729T3 (enExample) |
| MX (2) | MXPA04008100A (enExample) |
| NO (1) | NO20043913L (enExample) |
| NZ (2) | NZ535456A (enExample) |
| PT (1) | PT1476138E (enExample) |
| SI (1) | SI1476138T1 (enExample) |
| WO (2) | WO2003072089A1 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ260408A (en) | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
| ES2377729T3 (es) | 2002-02-21 | 2012-03-30 | Valeant International (Barbados) Srl | Formulaciones de liberación modificada de al menos una forma de tramadol |
| US8128957B1 (en) * | 2002-02-21 | 2012-03-06 | Valeant International (Barbados) Srl | Modified release compositions of at least one form of tramadol |
| US8323692B2 (en) * | 2002-02-21 | 2012-12-04 | Valeant International Bermuda | Controlled release dosage forms |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7413749B2 (en) | 2003-03-11 | 2008-08-19 | Purdue Pharma L.P. | Titration dosing regimen for controlled release tramadol |
| EP1905435A3 (en) * | 2003-03-11 | 2008-05-14 | Euro-Celtique S.A. | Titration dosing regimen for controlled release tramadol |
| BRPI0318456B8 (pt) * | 2003-08-08 | 2021-05-25 | Biovail Laboratories Int Srl | tablete com liberação modificada |
| US7206632B2 (en) | 2003-10-02 | 2007-04-17 | Medtronic, Inc. | Patient sensory response evaluation for neuromodulation efficacy rating |
| US20050074469A1 (en) * | 2003-10-03 | 2005-04-07 | Charles Signorino | Stable lipophilic emulsions for acrylic coating and method of making |
| US20060172006A1 (en) * | 2003-10-10 | 2006-08-03 | Vincent Lenaerts | Sustained-release tramadol formulations with 24-hour clinical efficacy |
| US20050084531A1 (en) * | 2003-10-16 | 2005-04-21 | Jatin Desai | Tablet with aqueous-based sustained release coating |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| US8586085B2 (en) * | 2004-11-08 | 2013-11-19 | Biokey, Inc. | Methods and formulations for making pharmaceutical compositions containing bupropion |
| US20060099261A1 (en) * | 2004-11-08 | 2006-05-11 | Biokey, Inc. | Methods and formulations for making controlled release oral dosage form |
| US20060099262A1 (en) * | 2004-11-08 | 2006-05-11 | Biokey, Inc. | Methods and formulations for making controlled release oral dosage form |
| US20080096979A1 (en) * | 2004-11-08 | 2008-04-24 | Rubicon Research Pvt. Ltd. | Aqueous Pharmaceutical Coating |
| ZA200711123B (en) | 2005-06-27 | 2009-08-26 | Biovail Lab Int Srl | Modified-release formulations of a bupropion salt |
| BRPI0612802A2 (pt) * | 2005-07-07 | 2010-11-30 | Farnam Co Inc | composições farmacêuticas de liberação sustentada para medicamentos extremamente hidrossolúveis |
| US8778395B2 (en) * | 2005-08-11 | 2014-07-15 | Andrx Labs, Llc | Diltiazem controlled release formulation and method of manufacture |
| BRPI0615860B8 (pt) | 2005-09-09 | 2021-05-25 | Labopharm Barbados Ltd | composição farmacêutica de liberação prolongada monolítica sólida |
| EP1956013B1 (en) * | 2005-11-30 | 2016-04-13 | Fujifilm RI Pharma Co., Ltd. | Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition |
| ES2279715B1 (es) * | 2005-12-26 | 2008-06-01 | Laboratorios Lesvi, S.L. | Formulacion oral de olanzapina. |
| NZ600394A (en) | 2006-05-04 | 2014-04-30 | Boehringer Ingelheim Int | Polymorphs of a dpp-iv enzyme inhibitor |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| US20070264335A1 (en) * | 2006-05-09 | 2007-11-15 | Sherman Bernard C | Modified release tablets comprising tramadol |
| CZ300698B6 (cs) * | 2006-06-16 | 2009-07-22 | Zentiva, A. S. | Tableta s obsahem metforminu |
| WO2008008801A2 (en) * | 2006-07-11 | 2008-01-17 | Mcneil Nutritionals, Llc | Solid oral dosage vitamin and mineral compositions |
| US7674479B2 (en) | 2006-07-25 | 2010-03-09 | Intelgenx Corp. | Sustained-release bupropion and bupropion/mecamylamine tablets |
| US8703191B2 (en) * | 2006-07-25 | 2014-04-22 | Intelgenx Corp. | Controlled-release pharmaceutical tablets |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
| AR071375A1 (es) * | 2008-04-22 | 2010-06-16 | Solvay Pharm Gmbh | Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| CA2638240C (en) | 2008-08-29 | 2010-02-02 | Alexander Macgregor | Method of treating dysglycemia and glucose excursions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| AU2010212867B2 (en) | 2009-02-13 | 2013-05-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof |
| CN102753161A (zh) | 2009-11-27 | 2012-10-24 | 贝林格尔.英格海姆国际有限公司 | 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗 |
| US20110136815A1 (en) * | 2009-12-08 | 2011-06-09 | Horst Zerbe | Solid oral film dosage forms and methods for making same |
| US10610528B2 (en) | 2009-12-08 | 2020-04-07 | Intelgenx Corp. | Solid oral film dosage forms and methods for making same |
| CA2785860A1 (en) * | 2009-12-29 | 2011-07-28 | Impax Laboratories, Inc. | Gastroretentive solid oral dosage forms with swellable hydrophilic polymer |
| CN107961377B (zh) | 2010-05-05 | 2022-11-22 | 勃林格殷格翰国际有限公司 | 组合疗法 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
| PL2731947T3 (pl) | 2011-07-15 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| US20130303554A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in sirs and/or sepsis |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| FI126168B (en) | 2012-09-18 | 2016-07-29 | Novaldmedical Ltd Oy | A method for coating pharmaceutical substrates |
| US9532946B2 (en) | 2012-11-20 | 2017-01-03 | Intervet Inc. | Manufacturing of semi-plastic pharmaceutical dosage units |
| CA2919892C (en) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015128453A1 (en) | 2014-02-28 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Medical use of a dpp-4 inhibitor |
| EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| CA3022202A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| JP2018043198A (ja) * | 2016-09-15 | 2018-03-22 | トヨタ自動車株式会社 | 粉粒体混合機 |
| BR112019012171B1 (pt) * | 2016-12-15 | 2021-02-09 | Spero Therapeutics, Inc | novas formas de dosagem oral de liberação modificada e imediata de tebipenem pivoxil |
| US11311491B2 (en) | 2018-01-16 | 2022-04-26 | Applied Materials, Inc. | Metal oxide encapsulated drug compositions and methods of preparing the same |
| DE102018001601A1 (de) * | 2018-03-01 | 2019-09-05 | Mann+Hummel Gmbh | Koaleszenzabscheider, insbesondere zur Verwendung in einem Kompressordruckluftsystem, Kompressordruckluftsystem sowie Verwendung eines Koaleszenzabscheiders |
| BR112022002962A2 (pt) | 2019-08-16 | 2022-07-05 | Applied Molecular Transport Inc | Composições, formulações e produção e purificação de interleucina |
| KR20220051250A (ko) | 2019-08-27 | 2022-04-26 | 어플라이드 머티어리얼스, 인코포레이티드 | 약제 남용 억제 제형들을 위한 증기상 코팅 기술 |
| TWI870622B (zh) | 2020-10-02 | 2025-01-21 | 美商應用材料股份有限公司 | 製備氧化矽塗佈藥品的低溫處理 |
| US12048691B2 (en) | 2020-11-11 | 2024-07-30 | Spero Therapeutics, Inc. | High dosage tebipenem pivoxil tablet formulation |
| US12491165B2 (en) | 2021-09-30 | 2025-12-09 | Applied Materials, Inc. | Low temperature silicon oxide coating for pharmaceutical applications |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3097144A (en) * | 1960-10-14 | 1963-07-09 | Upjohn Co | Heat-cured, polymeric, medicinal dosage film coatings containing a polyvinylpyrrolidone copolymer, polyethenoid acid, and polyethylene glycol |
| US4800087A (en) * | 1986-11-24 | 1989-01-24 | Mehta Atul M | Taste-masked pharmaceutical compositions |
| JPS63215620A (ja) * | 1987-03-03 | 1988-09-08 | Nippon Soda Co Ltd | 徐放性製剤 |
| GB8707416D0 (en) * | 1987-03-27 | 1987-04-29 | Wellcome Found | Pharmaceutical formulations |
| GB8724763D0 (en) * | 1987-10-22 | 1987-11-25 | Aps Research Ltd | Sustained-release formulations |
| JP2700662B2 (ja) * | 1988-06-22 | 1998-01-21 | 大正製薬株式会社 | 被覆製剤 |
| EP0386440B1 (de) * | 1989-02-11 | 1992-08-05 | Bayer Ag | Arzneimittel mit kontrollierter Wirkstoffabgabe |
| US5292522A (en) * | 1989-06-20 | 1994-03-08 | Rohm Gmbh | Aqueous film coating agent for solid medicaments |
| JPH05506011A (ja) | 1990-04-11 | 1993-09-02 | ジ・アップジョン・カンパニー | 流動床コーティングによるイブプロフェンの味覚マスキング |
| US5288505A (en) | 1991-06-26 | 1994-02-22 | Galephar P.R., Inc., Ltd. | Extended release form of diltiazem |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5376384A (en) * | 1992-12-23 | 1994-12-27 | Kinaform Technology, Inc. | Delayed, sustained-release pharmaceutical preparation |
| NZ260408A (en) * | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
| EP0804174A4 (en) * | 1993-07-21 | 1998-09-09 | Univ Kentucky Res Found | MULTI-CHAMBER HARD CAPSULES WITH CONTROLLED DELIVERY CHARACTERISTICS |
| US5458888A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
| US5733575A (en) * | 1994-10-07 | 1998-03-31 | Bpsi Holdings, Inc. | Enteric film coating compositions, method of coating therewith, and coated forms |
| US5871776A (en) | 1995-01-31 | 1999-02-16 | Mehta; Atul M. | Controlled-release nifedipine |
| DE19615812A1 (de) | 1996-04-20 | 1997-10-23 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation |
| DE19630035A1 (de) * | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
| WO1998027967A1 (en) | 1996-12-20 | 1998-07-02 | Dumex-Alpharma A/S | Release-controlled coated tablets |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US5788987A (en) | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
| ATE322892T1 (de) * | 1997-07-02 | 2006-04-15 | Euro Celtique Sa | Stabilisierte tramadol formulierungen mit verzögerter freisetzung |
| US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
| CA2312990C (en) * | 1997-12-08 | 2008-04-29 | Bristol-Myers Squibb Company | Novel salts of metformin and method |
| US6022554A (en) * | 1997-12-15 | 2000-02-08 | American Home Products Corporation | Polymeric microporous film coated subcutaneous implant |
| US6245357B1 (en) * | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
| US6156342A (en) | 1998-05-26 | 2000-12-05 | Andex Pharmaceuticals, Inc. | Controlled release oral dosage form |
| DE19826517B4 (de) | 1998-06-15 | 2006-03-23 | Baxter Healthcare S.A. | Verfahren zur Herstellung von Filmtabletten mit Cyclophosphamid als Wirkstoff und daraus hergestellte Cyclophosphamid-Filmtablette |
| EP0974356B1 (en) * | 1998-07-15 | 2003-09-24 | Merck Sante | Tablets comprising a combination of metformin and glibenclamide |
| UA73092C2 (uk) * | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
| DE19901686A1 (de) * | 1999-01-18 | 2000-07-20 | Gruenenthal Gmbh | Retardierte Tramadolzubereitungen mit einem lagerstabilen Freisetzungsprofil und Verfahren zu deren Herstellung |
| IN191482B (enExample) | 1999-03-19 | 2003-12-06 | Ranbaxy Lab Ltd | |
| US6183779B1 (en) * | 1999-03-22 | 2001-02-06 | Pharmascience Inc. | Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin |
| WO2001015683A1 (de) * | 1999-08-31 | 2001-03-08 | Grünenthal GmbH | Retardierte darreichungsform enthaltend tramadolsaccharinat |
| DE19940740A1 (de) * | 1999-08-31 | 2001-03-01 | Gruenenthal Gmbh | Pharmazeutische Salze |
| WO2001045668A2 (en) * | 1999-12-20 | 2001-06-28 | Schering Corporation | Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine |
| US6419956B1 (en) * | 1999-12-30 | 2002-07-16 | Ancile Pharmaceuticals | Odor-masking coating for a pharmaceutical preparation |
| AU767812B2 (en) * | 2000-02-04 | 2003-11-27 | Depomed, Inc. | Shell-and-core dosage form approaching zero-order drug release |
| US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
| US6676966B1 (en) * | 2000-05-09 | 2004-01-13 | Intellipharmaceutics Corp. | Extended release metformin hydrochloride formulations |
| IN192159B (enExample) * | 2000-05-15 | 2004-02-28 | Ranbaxy Lab Ltd | |
| US6620439B1 (en) * | 2000-10-03 | 2003-09-16 | Atul M. Mehta | Chrono delivery formulations and method of use thereof |
| US6866866B1 (en) * | 2000-11-03 | 2005-03-15 | Andrx Labs, Llc | Controlled release metformin compositions |
| US6749867B2 (en) | 2000-11-29 | 2004-06-15 | Joseph R. Robinson | Delivery system for omeprazole and its salts |
| SE0100200D0 (sv) * | 2001-01-24 | 2001-01-24 | Astrazeneca Ab | New film coating |
| ITMI20010220A1 (it) | 2001-02-05 | 2002-08-05 | Valpharma Sa | Formulazioni multiparticolate per somministrazione orale di sali di litio idonee per una somministrazione al giorno |
| WO2002074285A1 (en) | 2001-03-16 | 2002-09-26 | Andrx Corporation | Controlled release sulfonylurea formulation |
| US7858118B2 (en) * | 2001-04-11 | 2010-12-28 | Galephar Pharmaceutical Research, Inc. | Extended release composition containing Tramadol |
| JP5138856B2 (ja) * | 2001-06-20 | 2013-02-06 | 武田薬品工業株式会社 | 錠剤の製造方法 |
| MXPA04002891A (es) * | 2001-09-28 | 2005-06-20 | Johnson & Johnson | Composicion farmaceutica a base de pasta de azucar. |
| US20040126428A1 (en) * | 2001-11-02 | 2004-07-01 | Lyn Hughes | Pharmaceutical formulation including a resinate and an aversive agent |
| US6723348B2 (en) | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
| US20030118647A1 (en) * | 2001-12-04 | 2003-06-26 | Pawan Seth | Extended release tablet of metformin |
| US6667054B2 (en) * | 2001-12-05 | 2003-12-23 | Bernard Charles Sherman | Metformin hydrochloride tablets |
| TWI252111B (en) * | 2001-12-14 | 2006-04-01 | Solvay Pharm Gmbh | Matrix film tablet with controlled release of a natural mixture of conjugated estrogens |
| RU2323717C2 (ru) | 2001-12-19 | 2008-05-10 | Астразенека Аб | Новое пленочное покрытие |
| AU2002217373A1 (en) * | 2002-01-03 | 2003-07-15 | Lek Pharmaceutical And Chemical Company D.D. | Controlled release pharmaceutical formulation containing venlafaxine |
| JP2003290319A (ja) * | 2002-01-30 | 2003-10-14 | Takeda Chem Ind Ltd | 錠剤の製造装置 |
| ES2377729T3 (es) | 2002-02-21 | 2012-03-30 | Valeant International (Barbados) Srl | Formulaciones de liberación modificada de al menos una forma de tramadol |
| AU2003225102A1 (en) | 2002-04-23 | 2003-11-10 | Bristol-Myers Squibb Company | Modified-release vasopeptidase inhibitor formulation, combinations and method |
| US6902746B2 (en) | 2002-07-03 | 2005-06-07 | Yung Shin Pharmaceutical Industrial Co., Ltd. | Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same |
| SE0202353D0 (sv) * | 2002-08-01 | 2002-08-01 | Astrazeneca Ab | New film coating |
| US7429619B2 (en) | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US8216609B2 (en) * | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
| US7018658B2 (en) * | 2002-11-14 | 2006-03-28 | Synthon Bv | Pharmaceutical pellets comprising tamsulosin |
| DE10260919A1 (de) | 2002-12-20 | 2004-07-01 | Röhm GmbH & Co. KG | Verfahren zur Herstellung von überzogenen Arzneiformen und Nahrungsergänzungsmitteln mit Konzentrationsgradienten im Überzug |
| US20040185097A1 (en) * | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
| US20050048118A1 (en) * | 2003-07-25 | 2005-03-03 | Joan Cucala Escoi | Modified release venlafaxine hydrochloride tablets |
| US20050025829A1 (en) * | 2003-07-29 | 2005-02-03 | Kim Cherng-Ju | Controlled drug release tablets |
| US20050123596A1 (en) * | 2003-09-23 | 2005-06-09 | Kohane Daniel S. | pH-triggered microparticles |
| EP1523981A1 (en) * | 2003-10-13 | 2005-04-20 | Wyeth | Extended release formulations of venlafaxine |
| US20050084531A1 (en) * | 2003-10-16 | 2005-04-21 | Jatin Desai | Tablet with aqueous-based sustained release coating |
| ZA200711123B (en) * | 2005-06-27 | 2009-08-26 | Biovail Lab Int Srl | Modified-release formulations of a bupropion salt |
| US7671094B2 (en) * | 2005-06-27 | 2010-03-02 | Biovail Laboratories International S.R.L. | Bupropion hydrobromide and therapeutic applications |
-
2003
- 2003-02-21 ES ES03743147T patent/ES2377729T3/es not_active Expired - Lifetime
- 2003-02-21 CA CA002476496A patent/CA2476496C/en not_active Expired - Fee Related
- 2003-02-21 SI SI200332108T patent/SI1476138T1/sl unknown
- 2003-02-21 CA CA002476201A patent/CA2476201C/en not_active Expired - Fee Related
- 2003-02-21 AU AU2003211146A patent/AU2003211146B2/en not_active Expired
- 2003-02-21 EP EP03743148.3A patent/EP1476139B1/en not_active Expired - Lifetime
- 2003-02-21 JP JP2003570772A patent/JP5069395B2/ja not_active Expired - Fee Related
- 2003-02-21 MX MXPA04008100A patent/MXPA04008100A/es active IP Right Grant
- 2003-02-21 AU AU2003211145A patent/AU2003211145B2/en not_active Ceased
- 2003-02-21 JP JP2003570835A patent/JP4704685B2/ja not_active Expired - Lifetime
- 2003-02-21 DK DK03743147.5T patent/DK1476138T3/da active
- 2003-02-21 NZ NZ535456A patent/NZ535456A/en not_active IP Right Cessation
- 2003-02-21 ES ES03743148.3T patent/ES2627842T3/es not_active Expired - Lifetime
- 2003-02-21 MX MXPA04008164A patent/MXPA04008164A/es active IP Right Grant
- 2003-02-21 WO PCT/US2003/004867 patent/WO2003072089A1/en not_active Ceased
- 2003-02-21 EP EP03743147A patent/EP1476138B8/en not_active Expired - Lifetime
- 2003-02-21 PT PT03743147T patent/PT1476138E/pt unknown
- 2003-02-21 WO PCT/US2003/004866 patent/WO2003072025A2/en not_active Ceased
- 2003-02-21 US US10/370,109 patent/US7780987B2/en not_active Expired - Lifetime
- 2003-02-21 NZ NZ535455A patent/NZ535455A/en not_active IP Right Cessation
- 2003-02-21 AT AT03743147T patent/ATE536173T1/de active
-
2004
- 2004-09-20 NO NO20043913A patent/NO20043913L/no not_active Application Discontinuation
-
2008
- 2008-07-09 US US12/169,852 patent/US20080274177A1/en not_active Abandoned
-
2010
- 2010-04-05 JP JP2010086646A patent/JP2010155864A/ja active Pending
-
2012
- 2012-02-13 CY CY20121100144T patent/CY1112517T1/el unknown
-
2013
- 2013-05-13 US US13/892,657 patent/US20130245154A1/en not_active Abandoned
-
2014
- 2014-04-25 US US14/262,622 patent/US20150030675A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04008100A (es) | Formulaciones de liberacion modificada de al menos una forma de tramadol. | |
| KR101573889B1 (ko) | 속효성과 지속성을 동시에 갖는 약제학적 조성물 | |
| KR101784777B1 (ko) | 타펜타돌 조성물 | |
| CN102791258B (zh) | 雷沙吉兰的延长释放制剂及其用途 | |
| KR0140492B1 (ko) | 방출억제성 오피오이드 제형 | |
| US9468633B2 (en) | Oral controlled release dosage form | |
| US20050038042A1 (en) | Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders | |
| TW201206501A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| AU2009265099A1 (en) | Sustained release pharmaceutical compositions comprising Quetiapine | |
| US20090269402A1 (en) | Modified release composition of at least one form of venlafaxine | |
| US20080175873A1 (en) | Modified release composition of at least one form of venlafaxine | |
| US20050182056A9 (en) | Modified release formulations of at least one form of tramadol | |
| US8158147B2 (en) | Modified release formulations of at least one form of tramadol | |
| US20060099249A1 (en) | Modified release formulations of at least one form of tramadol | |
| US20050244498A1 (en) | Modified-release compositions of at least one form of venlafaxine | |
| US20190151246A1 (en) | Delayed-release tablets of methylphenidate | |
| CZ20033294A3 (cs) | Potahovaná tableta s obsahem venlafaxinu nebo jeho solí s řízeným uvolňováním | |
| NZ609568B2 (en) | Modified release pharmaceutical compositions of desvenlafaxine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights | ||
| FG | Grant or registration |